

GetReal: from efficacy in clinical trials to relative effectiveness in the real world

Matthias Egger^{a,b*}, Karel G. M. Moons^{c,d}, Christine Fletcher^e and GetReal Workpackage 4

Q1

The GetReal consortium (“incorporating real-life data into drug development”) addresses the efficacy–effectiveness gap that opens between the data from well-controlled randomized trials in selected patient groups submitted to regulators and the real-world evidence on effectiveness and safety of drugs required by decision makers. Workpackage 4 of GetReal develops evidence synthesis and modelling approaches to generate the real-world evidence. In this commentary, we discuss how questions change when moving from the well-controlled randomized trial setting to real-life medical practice, the evidence required to answer these questions, the populations to which estimates will be applicable to and the methods and data sources used to produce these estimates. We then introduce the methodological reviews written by GetReal authors and published in *Research Synthesis Methods* on network meta-analysis (Efthimiou *et al.*, 2016), individual patient data meta-analysis (Debray *et al.*, 2015) and mathematical modelling to predict drug effectiveness (Panayidou *et al.*, 2016). The critical reviews of key methods are a good starting point for the ambitious programme of work GetReal has embarked on. The different strands of work under way in GetReal have great potential to contribute to making clinical trials research as relevant as it can be to patients, caregivers and policy makers. Copyright © 2016 John Wiley & Sons, Ltd.

The randomized clinical trial is the most reliable study design to determine the efficacy and safety of drugs. However, the clinical trials system has been described as “broken,” “in crisis” and “not fit for purpose”: many trials do not achieve patient enrolment targets; spiralling costs and complex regulatory and monitoring requirements prevent the conduct of others; and many completed trials do not answer clinically relevant questions or are not applicable to everyday medical practice but are driven by commercial considerations (DeVita, 2008; Vickers, 2014; Loudon *et al.*, 2013). As a consequence, fewer trials that are relevant to patients, caregivers and policy makers are carried out, and the evidence on the benefits and risks of drugs is becoming less reliable.

Several initiatives have been established in recent years to remedy this situation. In the USA, Duke University and the Food and Drug Administration established CTTI, the Clinical Trials Transformation Initiative (Tenaerts *et al.*, 2014). CTTI’s mission is “to promote practices that will increase the quality and efficiency of clinical trials,” with the aim to create a clinical trials system that is “patient centered and efficient, enabling reliable and timely access to evidence-based prevention and treatment options.” The initiative has generated evidence and formulated recommendations, for example, to streamline risk-based trial monitoring and the ethical review process. Similarly, Oxford University in the UK, McMaster University in Canada and Duke have joined forces to form the Sensible Guidelines Group to “rid clinical trials of undue bureaucracy, maximize patient safety, and improve the efficiency of reaching valid conclusions from large multi-centre randomized studies” (Shurlock, 2013).

Launched in October 2013, “GetReal: Incorporating real-life data into drug development” of the European Union’s Innovative Medicines Initiative is another important development to enhance the efficiency of randomized trials and the quantification of effectiveness and safety of drugs in real-world medical practice. GetReal is a public–private consortium consisting of academia, pharmaceutical companies, health technology assessment agencies, regulators and patient organizations (GetReal consortium). GetReal addresses the

^aInstitute of Social and Preventive Medicine (ISPM), University of Bern, Bern, Switzerland

^bDepartment of Clinical Research, Clinical Trials Unit, University of Bern, Bern, Switzerland

^cJulius Center for Health Sciences and Primary Care, University Medical Center Utrecht, Utrecht, The Netherlands

^dCochrane Netherlands, Julius Center for Health Sciences and Primary Care, University Medical Center Utrecht, Utrecht, The Netherlands

^eAmgen Ltd, Cambridge, UK

*Correspondence to: Matthias Egger, Institute of Social and Preventive Medicine (ISPM), University of Bern, Bern, Switzerland.

E-mail: egger@ispm.unibe.ch

“efficacy–effectiveness gap” (Eichler *et al.*, 2011) that opens between the data from well-controlled randomized studies in selected patient groups submitted to regulators and the real-world evidence (RWE) on effectiveness and safety of drugs, required by decision makers. Decisions on whether a new drug should be made available in a national health system or reimbursed by social insurance requires evidence on its relative effectiveness and safety compared with established treatments and the wider implications including costs of introducing a new therapy. Ideally, such evidence should be made available to regulatory and health technology assessment agencies before the drug enters the market.

GetReal aims to develop methods and tools that support the generation of RWE on the relative effectiveness of new drugs that could inform decision-making before the drug is launched. The GetReal consortium works with stakeholders to

- (i) develop a framework for the acceptability of RWE for estimating the effectiveness of new medicines (*workpackage 1*),
- (ii) study the scientific validity of RWE, including non-randomized study designs, and analytical approaches and drivers of effectiveness (*workpackage 2*),
- (iii) examine the challenges and possible solutions to performing pragmatic trials earlier in the development process, in particular prelaunch or peri-launch (*workpackage 3*),
- (iv) develop evidence synthesis and modelling approaches to generate RWE, based on combination of both randomized and observational study data (*workpackage 4*)

Workpackage 4 will be of particular interest to the readership of *Research Synthesis Methods*. In workpackage 4, we examine how estimates of the *relative efficacy* of drugs in clinical trial populations, their *relative effectiveness in real world populations* and their *relative effectiveness in the real world* of a healthcare systems can best be obtained, using data from phase II/III clinical trials and from real-world clinical databases and registries. Table 1 summarizes the questions asked, moving from the randomized clinical trial setting to real-life medical practice, the evidence required to answer these questions, the populations to which estimates will be applicable to and the methods and data sources used to produce these estimates.

We use case studies of the treatment of chronic diseases, for example, schizophrenia, depression and rheumatoid arthritis, to examine different methodological approaches for combining both randomized and observational study data, both using aggregate study data and using individual participant data. For example,

Table 1. From efficacy to relative effectiveness in the real world.					
Steps and questions	Outcomes of interest	Applicability to patient populations	Data sources	Methodology	Conditions
1) How efficacious and safe is this drug?	Efficacy, safety	Typical patients included in clinical trials	Phase II/III randomised clinical trials	Clinical trials, standard meta-analysis	Study conditions
2) How efficacious and safe is this drug compared with alternative therapies?	Relative efficacy, relative safety	Typical patients included in clinical trials	Phase II/III randomised clinical trials	Network meta-analysis	Study conditions
3) How effective and safe is this drug compared with alternative therapies, in patients who will likely receive it post-launch?	Relative effectiveness, relative safety in predicted study populations	Patients predicted to receive the drug post-launch	Phase II/III randomised clinical trials, clinical databases and registries	Individual patient data network meta-analysis and meta-regression	Study conditions
4) How effective and safe is this drug compared with alternative therapies, in the patients who will likely receive it in the real world of a healthcare system?	Relative effectiveness, relative safety in predicted real-world populations	Patients predicted to receive the drug post-launch in a given healthcare system	Phase II/III randomised clinical trials, clinical databases and registries, expert opinion, patient preferences	Mathematical modelling	Real-world conditions

we use network meta-analysis approaches of aggregate study results to obtain estimates of relative efficacy from several randomized trials. One of the drugs in the network is, for the sake of the argument, designated as the “new kid on the block,” and the trials of this drug are assumed to be prelaunch, whereas the other drugs are assumed to be on the market. Subsequently, individual participant data (IPD) provided by the participating pharmaceutical companies and observational data from clinical databases and disease registries are combined to identify important factors that modify the drug’s relative effectiveness and to estimate its performance in patient populations that will likely receive the drug after launch. Of note, at this stage, the relative effectiveness of the drug continues to be estimated under randomized study conditions, rather than real-world conditions (Table 1). For example, adherence to treatments is implicitly assumed to correspond to that observed in the phase II/III trials.

The next step is to account for the messy real world, where doctors decide who will receive the new drug, influenced by guidelines, patient characteristics and preferences, and other factors. In order to gauge relative effectiveness, these decisions need to be understood as well as the possible confounding factors that may be associated with the probability both of receiving the drug and of developing the outcome and the variables that may be associated with the treatment (but not with the outcomes) or of variables associated with outcomes (but not treatment). The likely adherence to the new drug and to the comparator drugs is also relevant. Empirical evidence on these factors will typically be scarce, or absent. Drawing directed acyclic graphs and in-depth discussions with clinicians are helpful to understand how the different variables are likely to interact and what predictive model might be most appropriate (Westreich and Edwards, 2015).

It is good practice first to critically review the methods and applications that will be important in a research programme, to gain an understanding of the relevant strengths and limitations. In this issue and a previous issue of the journal, GetReal investigators present reviews of common methods used for network meta-analysis (Efthimiou *et al.*, 2016), IPD meta-analysis (Debray *et al.*, 2015) and mathematical modelling to predict drug effectiveness (Panayidou *et al.*, 2016). In their review of network meta-analysis methods, Efthimiou *et al.* summarize the key issues involved, including novel methods for measuring and detecting inconsistency in the network, dealing with effect modification, ways for adjusting for possible sources of bias and the reporting of the results of a network meta-analysis (Efthimiou *et al.*, 2016). IPD meta-analysis is widely considered to be the gold standard in meta-analytic research, but in their review, Debray *et al.* stress that they are no panacea to the limitations of the included studies. Also, IPD meta-analyses are major undertakings, which cannot be performed *ad hoc* or on a shoe string, and their potential advantages, for example, the powerful investigation of interaction and subgroup effects, must be carefully weighed against the extra efforts involved (Debray *et al.*, 2015). Finally, Panayidou and colleagues comprehensively searched for studies that predicted real-world effectiveness from randomized controlled trial data. Of note, they found only 12 articles and four modelling approaches, mainly Markov multistate models (Panayidou *et al.*, 2016). Although most studies included sensitivity analyses, external validation was rarely performed.

The critical reviews of the key methodologies published in the *Research Synthesis Methods* are a good starting point for the ambitious programme of work the GetReal consortium has embarked on. The different strands of work under way in GetReal have great potential to contribute to making clinical trials research as relevant as it can possibly be to patients, caregivers and policy makers. Watch this space!

Acknowledgements

This work was conducted as part of the GetReal consortium. For further information, please refer to <http://www.imi-getreal.eu>. This commentary reflects the personal views of the authors. The authors are grateful to Georgia Salanti and Eva-Maria Didden for helpful comments on an earlier draft.

References

- Debray TPA *et al.* 2015. Get real in individual participant data (IPD) meta-analysis: a review of the methodology. *Research Synthesis Methods* 6(4): 293–309.
- DeVita VT 2008. The clinical trials system is broken. *Nature Clinical Practice. Oncology* 5(12): 683.
- Efthimiou O *et al.* 2016. GetReal in network meta-analysis: a review of the methodology. *Research Synthesis Methods* in press. Q4
- Eichler H-G *et al.* 2011. Bridging the efficacy–effectiveness gap: a regulator’s perspective on addressing variability of drug response. *Nature Reviews Drug Discovery* 10(7): 495–506.
- GetReal consortium, IMI GetReal - real-life data in drug development. Available at: <http://www.imi-getreal.eu/> [Accessed February 13, 2016]. Q5
- Loudon K *et al.* 2013. Making clinical trials more relevant: improving and validating the PRECIS tool for matching trial design decisions to trial purpose. *Trials* 14: 115.

- 1 Panayidou K *et al.* 2016. GetReal in mathematical modelling: a review of studies predicting drug effectiveness in
2 the real world. *Research Synthesis Methods* in press. 1
- 3 Shurlock B. 2013. Sensible guidelines for clinical trials: are current European regulations “a gift to America”? 2
- 4 *European Heart Journal* 34(24): 1767–1768. 3
- 5 Tenaerts P *et al.* 2014. The Clinical Trials Transformation Initiative: innovation through collaboration. *Nature*
6 *Publishing Group*, 13. 4
- 7 Vickers AJ. 2014. Clinical trials in crisis: four simple methodologic fixes. *Clinical Trials (London, England)* 11(6): 615–21. 5
- 8 Westreich D, Edwards JK. 2015. Invited commentary: every good randomization deserves observation. *American*
9 *Journal of Epidemiology* 182(10): 857–60. 6
- 10 7
- 11 8
- 12 9
- 13 10
- 14 11
- 15 12
- 16 13
- 17 14
- 18 15
- 19 16
- 20 17
- 21 18
- 22 19
- 23 20
- 24 21
- 25 22
- 26 23
- 27 24
- 28 25
- 29 26
- 30 27
- 31 28
- 32 29
- 33 30
- 34 31
- 35 32
- 36 33
- 37 34
- 38 35
- 39 36
- 40 37
- 41 38
- 42 39
- 43 40
- 44 41
- 45 42
- 46 43
- 47 44
- 48 45
- 49 46
- 50 47
- 51 48
- 52 49
- 53 50
- 54 51
- 55 52
- 56 53
- 57 54
- 58 55
- 59 56
- 60 57
- 61 58
- 62 59
- 63 60
- 64 61
- 65 62

Author Query Form

Journal: Research Synthesis Methods

Article: jrsm_1207

Dear Author,

During the copyediting of your paper, the following queries arose. Please respond to these by annotating your proofs with the necessary changes/additions.

- If you intend to annotate your proof electronically, please refer to the E-annotation guidelines.
- If you intend to annotate your proof by means of hard-copy mark-up, please use the standard proofing marks. If manually writing corrections on your proof and returning it by fax, do not write too close to the edge of the paper. Please remember that illegible mark-ups may delay publication.


Whether you opt for hard-copy or electronic annotation of your proofs, we recommend that you provide additional clarification of answers to queries by entering your answers on the query sheet, in addition to the text mark-up.

Query No.	Query	Remark
Q1	AUTHOR: Please confirm that given names (red) and surnames/ family names (green) have been identified correctly.	
Q2	AUTHOR: Please check that authors and their affiliations are correct.	
Q3	AUTHOR: Reference citations are not allowed in abstract section. Please reword texts (if necessary) and delete citations.	
Q4	AUTHOR: Please update any 'in press' references if available.	
Q5	AUTHOR: Reference "GetReal consortium, IMI GetReal -real-life data in drug development (n.d.)" is not cited in the text. Please indicate where it should be cited; or delete from the reference list.	
Q6	AUTHOR: Please update any 'in press' references if available.	
Q7	AUTHOR: Please provide the page range for Reference Tenaerts et al. (2014).	


Required software to e-annotate PDFs: [Adobe Acrobat Professional](#) or [Adobe Reader](#) (version 7.0 or above). (Note that this document uses screenshots from [Adobe Reader X](#))

The latest version of Acrobat Reader can be downloaded for free at: <http://get.adobe.com/uk/reader/>

Once you have Acrobat Reader open on your computer, click on the [Comment](#) tab at the right of the toolbar:



This will open up a panel down the right side of the document. The majority of tools you will use for annotating your proof will be in the [Annotations](#) section, pictured opposite. We've picked out some of these tools below:



1. **Replace (Ins) Tool** – for replacing text.



Strikes a line through text and opens up a text box where replacement text can be entered.

How to use it

- Highlight a word or sentence.
- Click on the [Replace \(Ins\)](#) icon in the Annotations section.
- Type the replacement text into the blue box that appears.

standard framework for the analysis of microeconomics. Nevertheless, it also led to exogenous growth. The number of competitors and the number of firms in the industry are not determined by the number of competitors and the number of firms in the industry. It is that the structure of the industry is determined by the number of competitors and the number of firms in the industry. The main components of the industry are the number of competitors and the number of firms in the industry. The level, are exogenous. The important works on this subject are by Kirman and Salmon (1982) and Kirman and Salmon (1982). Henceforth we use the term 'black box'.



2. **Strikethrough (Del) Tool** – for deleting text.



Strikes a red line through text that is to be deleted.

How to use it

- Highlight a word or sentence.
- Click on the [Strikethrough \(Del\)](#) icon in the Annotations section.

there is no room for extra profits and the number of firms is zero and the number of firms is zero and the number of firms is zero. The values are not determined by the number of firms. Blanchard and Kiyotaki (1987), perfect competition in general equilibrium. The structure of aggregate demand and supply in the classical framework assuming monopoly power. The number of firms is exogenous.

3. **Add note to text Tool** – for highlighting a section to be changed to bold or italic.




Highlights text in yellow and opens up a text box where comments can be entered.

How to use it

- Highlight the relevant section of text.
- Click on the [Add note to text](#) icon in the Annotations section.
- Type instruction on what should be changed regarding the text into the yellow box that appears.

dynamic responses of mark-ups to cost changes. The VAR evidence shows that the structure of the sector is dynamic.

with well-labeled demand curves. The number of competitors and the number of firms in the industry are not determined by the number of competitors and the number of firms in the industry. It is that the structure of the industry is determined by the number of competitors and the number of firms in the industry. The main components of the industry are the number of competitors and the number of firms in the industry. The level, are exogenous. The important works on this subject are by Kirman and Salmon (1982) and Kirman and Salmon (1982). Henceforth we use the term 'black box'.



4. **Add sticky note Tool** – for making notes at specific points in the text.



Marks a point in the proof where a comment needs to be highlighted.

How to use it

- Click on the [Add sticky note](#) icon in the Annotations section.
- Click at the point in the proof where the comment should be inserted.
- Type the comment into the yellow box that appears.

and supply shocks. Most of the time, the number of firms is zero and the number of firms is zero. The values are not determined by the number of firms. Blanchard and Kiyotaki (1987), perfect competition in general equilibrium. The structure of aggregate demand and supply in the classical framework assuming monopoly power. The number of firms is exogenous.




5. Attach File Tool – for inserting large amounts of text or replacement figures.



Inserts an icon linking to the attached file in the appropriate place in the text.

How to use it

- Click on the **Attach File** icon in the Annotations section.
- Click on the proof to where you'd like the attached file to be linked.
- Select the file to be attached from your computer or network.
- Select the colour and type of icon that will appear in the proof. Click OK.



6. Add stamp Tool – for approving a proof if no corrections are required.



Inserts a selected stamp onto an appropriate place in the proof.


How to use it

- Click on the **Add stamp** icon in the Annotations section.
- Select the stamp you want to use. (The **Approved** stamp is usually available directly in the menu that appears).
- Click on the proof where you'd like the stamp to appear. (Where a proof is to be approved as it is, this would normally be on the first page).

...of the business cycle, starting with the
 ...on perfect competition, constant ret
 ...roduction. In this environment goods
 ...extra profits and the structure of market
 ...he number of firms is determined by the model. The New-Key
 ...otaki (1987), has introduced produc
 ...general equilibrium models with nomin
 ...ed and supplybooks. Most of this literat



Drawing Markups




7. Drawing Markups Tools – for drawing shapes, lines and freeform annotations on proofs and commenting on these marks.

Allows shapes, lines and freeform annotations to be drawn on proofs and for comment to be made on these marks..

How to use it

- Click on one of the shapes in the **Drawing Markups** section.
- Click on the proof at the relevant point and draw the selected shape with the cursor.
- To add a comment to the drawn shape, move the cursor over the shape until an arrowhead appears.
- Double click on the shape and type any text in the red box that appears.



For further information on how to annotate proofs, click on the **Help** menu to reveal a list of further options:

